Apelin-13: A Promising Biomarker for Multiple Sclerosis?

Basit Öğe Kaydı
dc.contributor.authorAlpua, Murat
dc.contributor.authorTurkel, Yakup
dc.contributor.authorDag, Ersel
dc.contributor.authorKisa, Ucler
dc.date.accessioned2020-06-25T18:29:39Z
dc.date.available2020-06-25T18:29:39Z
dc.date.issued2018
dc.departmentKırıkkale Üniversitesi
dc.descriptionKISA, Ucler/0000-0002-8131-6810
dc.description.abstractObjectives: Recent studies have shown that Apelin 13 may have a neuroprotective property. Therefore it can be used as a biomarker for multiple sclerosis. Our purpose to assess serum apelin-13 levels in adult patients with multiple sclerosis and healthy controls. Patients and Methods: Subjects consisted of 42 relapsing remitting multiple sclerosis patients and 41 controls. Demographic characteristics including age, gender, duration of disease and Expanded Disability Symptom Scale (EDSS) were recorded. In serum samples obtained from the patients and controls, serum apelin-13 levels were measured with Enzyme Linked Immunosorbent Assay (ELISA) method. Results: Serum apelin-13 levels were significantly higher in the patients groups than the healthy controls (P = 0.003). Pearson analysis did not show any significant correlation between EDSS, disease duration and apelin-13 levels. Conclusion: The results of our study have been showed statistically significant higher levels of serum apelin-13 in multiple sclerosis patients compared to controls. Further studies with larger patients populations and healthy controls should be done to clarify to use serum apelin levels as a biomarker for multiple sclerosis.en_US
dc.description.sponsorshipKirikkale UniversityKirikkale Universityen_US
dc.description.sponsorshipThis study was funded by Kirikkale University.en_US
dc.identifier.citationAlpua M, Turkel Y, Dag E, Kisa U. Apelin-13: A promising biomarker for multiple sclerosis?. Ann Indian Acad Neurol 2018;21:126-9.en_US
dc.identifier.doi10.4103/aian.AIAN_377_17
dc.identifier.endpage129en_US
dc.identifier.issn0972-2327
dc.identifier.issn1998-3549
dc.identifier.issue2en_US
dc.identifier.pmid30122837
dc.identifier.scopus2-s2.0-85050811213
dc.identifier.scopusqualityQ3
dc.identifier.startpage126en_US
dc.identifier.urihttps://doi.org/10.4103/aian.AIAN_377_17
dc.identifier.urihttps://hdl.handle.net/20.500.12587/7411
dc.identifier.volume21en_US
dc.identifier.wosWOS:000439857300006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofAnnals Of Indian Academy Of Neurology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectApelin-13en_US
dc.subjectExpanded Disability Status Scaleen_US
dc.subjectrelapsing-remitting multiple sclerosisen_US
dc.titleApelin-13: A Promising Biomarker for Multiple Sclerosis?en_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Apelin-13 A Promising Biomarker for Multiple Sclerosis.pdf
Boyut:
453.53 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu